AdvisorShares Psychedelics ETF (PSIL)
| Assets | $20.25M |
| Expense Ratio | 0.99% |
| PE Ratio | n/a |
| Shares Out | 1.00M |
| Dividend (ttm) | $0.25 |
| Dividend Yield | 1.23% |
| Ex-Dividend Date | Sep 22, 2025 |
| Payout Frequency | Quarterly |
| Payout Ratio | n/a |
| Volume | 14,347 |
| Open | 19.60 |
| Previous Close | 19.87 |
| Day's Range | 19.18 - 20.38 |
| 52-Week Low | 9.58 |
| 52-Week High | 20.76 |
| Beta | 0.93 |
| Holdings | 28 |
| Inception Date | Sep 15, 2021 |
About PSIL
Fund Home PageThe AdvisorShares Psychedelics ETF (PSIL) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed to provide exposure to the emerging global psychedelics industry. PSIL was launched on Sep 15, 2021 and is issued by AdvisorShares.
Top 10 Holdings
69.11% of assets| Name | Symbol | Weight |
|---|---|---|
| Atai Life Sciences N.V. | ATAI | 14.53% |
| COMPASS Pathways plc | CMPS | 8.39% |
| Mind Medicine (MindMed) Inc. | MNMD | 8.17% |
| NRx Pharmaceuticals, Inc. | NRXP | 6.21% |
| Bright Minds Biosciences Inc. | DRUG | 5.67% |
| Neuphoria Therapeutics Inc. | NEUP | 5.47% |
| Supernus Pharmaceuticals, Inc. | SUPN | 5.37% |
| Vistagen Therapeutics, Inc. | VTGN | 5.36% |
| Alkermes plc | ALKS | 5.01% |
| Neurocrine Biosciences, Inc. | NBIX | 4.94% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 22, 2025 | $0.0201 | Sep 29, 2025 |
| Jun 23, 2025 | $0.0119 | Jun 27, 2025 |
| Mar 21, 2025 | $0.16343 | Mar 28, 2025 |
| Dec 23, 2024 | $0.0548 | Dec 30, 2024 |
| Sep 23, 2024 | $0.1087 | Sep 30, 2024 |
| Sep 25, 2023 | $0.0336 | Sep 29, 2023 |
Performance
PSIL had a total return of 50.15% in the past year, including dividends. Since the fund's inception, the average annual return has been -31.51%.
News
EXCLUSIVE: Investing In The Unique Growth Market Of Psychedelics - AdvisorShares Psychedelics ETF (ARCA:PSIL)
The global psychedelics market of drugs such as psilocybin, ketamine and LSD is booming and there are plenty of ways to get involved in the space.
Cannabis Is A Psychedelic - Dr. Julie Holland
Dr. Julie Holland on why cannabis is a psychedelic. The biggest risk in psychedelic treatment.
PSIL: When Investing In Psychedelic Firms, ETFs Are The Safer Route
There have been some exciting developments in the research around the medicinal potential of psychedelic compounds. Despite a potential opportunity for disruption, investors should keenly understand t...
The Growth Potential Of Psychedelics Stocks And ETFs
On July 13, 2022, two amendments passed in the House of Representatives that would provide psychedelic drug treatment to veterans and active duty service members. A documentary based on Michael Pollan...